About the Event
Most people haven’t heard of HIT (Heparin-Induced Thrombocytopenia), but as a side effect of one of the most common treatments for heart disease it affects as many as 300,000 people per year.
Heparin is used 12 to 15 million times per year in the US alone during cardiovascular procedures as a post-surgical anticoagulant. HIT is an allergic reaction that causes platelets to clot, which can result in stroke, amputation, and death. Importantly, it can take up to 7 days to establish a diagnosis of HIT, so physicians must treat those suspected of having the diseases while awaiting confirmation.
Veralox’s lead program VLX-1005 targets the root cause of HIT. In Phase 1 clinical trials, VLX-1005 saw no treatment-based discontinuations, no dose limiting toxicities, and no drug interactions between it and the current standard of care. VLX-1005 has received orphan drug and fast-track designation from the FDA and has begun Phase 2 clinical sites that include Stanford and Yale. Conservative estimates suggest that the market potential for HIT alone is between $850M and $1B.
Join our webinar with Veralox CEO, Jonathan Mow to hear the full story and hear why Hatteras Venture Partners, Genesys Capital, Sanofi Ventures, JDRF T1D Fund, and others have all backed the company.
